Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Top Cited Papers
- 26 November 2015
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 373 (22), 2117-2128
- https://doi.org/10.1056/nejmoa1504720
Abstract
The effects of empagliflozin, an inhibitor of sodium–glucose cotransporter 2, in addition to standard care, on cardiovascular morbidity and mortality in patients with type 2 diabetes at high cardiovascular risk are not known.Keywords
This publication has 26 references indexed in Scilit:
- Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 DiabetesNew England Journal of Medicine, 2015
- Association of Cardiometabolic Multimorbidity With MortalityJAMA, 2015
- Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trialsThe Lancet Diabetes & Endocrinology, 2015
- Probing SGLT2 as a therapeutic target for diabetes: Basic physiology and consequencesDiabetes and Vascular Disease Research, 2015
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes MellitusNew England Journal of Medicine, 2013
- Alogliptin after Acute Coronary Syndrome in Patients with Type 2 DiabetesNew England Journal of Medicine, 2013
- Empagliflozin, a novel selective sodium glucose cotransporter‐2 (SGLT‐2) inhibitor: characterisation and comparison with other SGLT‐2 inhibitorsDiabetes, Obesity and Metabolism, 2011
- Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studiesThe Lancet, 2010
- 10-Year Follow-up of Intensive Glucose Control in Type 2 DiabetesNew England Journal of Medicine, 2008
- Diabetes and AtherosclerosisJAMA, 2002